幽门螺杆菌治疗对胃癌发病率和死亡率预防作用的韩国人群研究
韩国一项基于916,438名≥20岁接受幽门螺杆菌根除治疗者的人群研究,随访至2021年,比较其与一般人群的胃癌标准化发病比和死亡比。结果显示除20-29岁组外各年龄组发病率和死亡率均显著更低,≥70岁组亦如此。结论认为根除治疗可能有助于预防胃癌和改善生存,年龄较大可能不是治疗的限制因素。
要点
- 除20-29岁组外,各年龄组接受幽门螺杆菌治疗者胃癌发病率和死亡率均显著低于一般人群。
- 70-74、75-79、≥80岁组的胃癌标准化发病比分别为0.56、0.48、0.36。
- 70-74、75-79、≥80岁组的胃癌标准化死亡比分别为0.30、0.38、0.43。
核心结论
- 幽门螺杆菌根除治疗可能有助于预防胃癌和改善各年龄成人的生存,包括≥70岁者。
- 这些发现提示根除治疗不仅使较年轻成人获益,也使较年长成人获益。
- 根除治疗在较年轻时更可取,但年龄较大可能不是治疗的限制因素。
研究设计与样本
- 韩国基于人群的研究,纳入2009年至2011年间接受幽门螺杆菌根除治疗的916,438名≥20岁个体,随访至2021年。
- 计算胃癌标准化发病比(SIR)和标准化死亡比(SMR),将接受治疗者与一般人群进行比较。
主要发现
- 平均随访期为12.4±1.1年。
- 除20-29岁组外,各年龄组(30-39、40-49、50-59、60-69、≥70岁)接受治疗者的胃癌发病率和死亡率均显著低于一般人群。
- 70-74岁组胃癌SIR为0.56(95%CI 0.52-0.61),75-79岁组为0.48(95%CI 0.42-0.54),≥80岁组为0.36(95%CI 0.28-0.46)。
- 70-74岁组胃癌SMR为0.30(95%CI 0.25-0.35),75-79岁组为0.38(95%CI 0.31-0.47),≥80岁组为0.43(95%CI 0.30-0.59)。
临床怎么用
- 作者认为幽门螺杆菌根除治疗可能有助于预防胃癌和改善生存,包括≥70岁成人。
- 作者认为根除治疗在较年轻时更可取,但年龄较大可能不是治疗的限制因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Helicobacter pylori (H pylori) infection is a major risk factor for gastric cancer (GC); however, whether H pylori eradication (HPE) benefits the older population remains unclear. We compared GC incidence and mortality between H pylori-treated individuals and the general population, stratified by age. METHODS: We conducted a population-based study in South Korea involving 916,438 individuals aged ≥20 years who underwent HPE therapy between 2009 and 2011, with follow-up until 2021. Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) for GC were calculated, comparing H pylori-treated individuals with the general population. RESULTS: The mean follow-up period was 12.4 ± 1.1 years. GC incidence and mortality rates were significantly lower in H pylori-treated individuals than in the general population across all age-groups (30-39, 40-49, 50-59, 60-69, and ≥70 years), except for the 20 to 29 years age-group. Notably, in the 70 to 74, 75 to 79, and ≥80 years age-groups, GC incidence and mortality in H pylori-treated individuals remained significantly lower. The SIRs for these groups were 0.56 (95% confidence interval [CI], 0.52-0.61), 0.48 (95% CI, 0.42-0.54), and 0.36 (95% CI, 0.28-0.46), respectively, and the SMRs were 0.30 (95% CI, 0.25-0.35), 0.38 (95% CI, 0.31-0.47), and 0.43 (95% CI, 0.30-0.59), respectively. CONCLUSIONS: HPE may help prevent GC and improve survival in adults of all ages, including those aged ≥70 years. These findings suggest that HPE benefits not only younger adults but also older adults. HPE treatment is preferable at a younger age, but older age may not be a limiting factor for the treatment.
引用
- Jung YS, Tran MTX, Park B, et al. Preventive Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study. Gastroenterology. 2025. PMID: 40209808. doi:10.1053/j.gastro.2025.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。